Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Schizophr Res. 2017 Jan 13;185:88–95. doi: 10.1016/j.schres.2017.01.008

Table 4.

Change from baseline for PANSS following 12 weeks of treatment

Oxytocin Placebo
Outcome Variablea Time
Point
(wks)
N LS Mean
(SE)
P-Valueb
Diff>0
N LS Mean
(SE)
P-Valueb
Diff>0
P-Valuec
Trt Diff
PANSS Total 2 32 −4.10
(1.35)
0.004 30 −6.13
(1.40)
0.000 0.310
6 28 −3.23
(1.49)
0.035 29 −5.56
(1.49)
0.000 0.279
9 27 −4.21
(1.69)
0.016 29 −4.77
(1.65)
0.006 0.815
12 26 −3.54
(1.60)
0.032 29 −5.49
(1.54)
0.001 0.389
PANSS Positive 2 32 −1.21
(0.43)
0.007 30 −1.40
(0.45)
0.003 0.774
6 28 −0.59
(0.55)
0.292 29 −1.68
(0.55)
0.003 0.168
9 27 −1.39
(0.60)
0.025 29 −1.50
(0.59)
0.014 0.894
12 26 −1.10
(0.56)
0.056 29 −1.49
(0.54)
0.008 0.614
PANSS Negative 2 32 −1.20
(0.52)
0.024 30 −0.65
(0.54)
0.232 0.467
6 28 −1.28
(0.62)
0.044 29 −0.36
(0.62)
0.558 0.303
9 27 −0.92
(0.55)
0.099 29 −0.13
(0.54)
0.816 0.309
12 26 −1.18
(0.59)
0.051 29 −0.64
(0.57)
0.261 0.521
PANSS General 2 32 −1.76
(0.84)
0.042 30 −4.02
(0.88)
0.000 0.071
6 28 −1.41
(0.79)
0.077 29 −3.46
(0.79)
0.000 0.076
9 27 −1.92
(1.10)
0.087 29 −3.08
(1.08)
0.006 0.460
12 26 −1.44
(0.93)
0.127 29 −3.28
(0.89)
0.001 0.164

Abbreviations: LS, least squares; PANSS, Positive and Negative Syndrome Scale

a

Models adjusted for baseline value and age in addition to treatment group.

b

Test for within-group change

c

Test for between-group change